When markets tell companies it’s more valuable to develop drugs that lengthen eyelashes than to develop drugs that treat malaria or tuberculosis, something is clearly wrong with the incentive structure. And we are not stuck with that incentive structure. I know, because the two most recent drugs developed to treat TB, bedaquiline and delamanid, were both funded primarily by public money.
